333 related articles for article (PubMed ID: 23212519)
1. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
2. The significance of CUX1 and chromosome 7 in myeloid malignancies.
Jotte MRM; McNerney ME
Curr Opin Hematol; 2022 Mar; 29(2):92-102. PubMed ID: 35084368
[TBL] [Abstract][Full Text] [Related]
3. Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia.
Supper E; Rudat S; Iyer V; Droop A; Wong K; Spinella JF; Thomas P; Sauvageau G; Adams DJ; Wong CC
Nat Commun; 2021 Apr; 12(1):2482. PubMed ID: 33931647
[TBL] [Abstract][Full Text] [Related]
4. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).
McNerney ME; Brown CD; Peterson AL; Banerjee M; Larson RA; Anastasi J; Le Beau MM; White KP
Br J Haematol; 2014 Aug; 166(4):550-6. PubMed ID: 24931631
[TBL] [Abstract][Full Text] [Related]
6. CUX1 in leukemia: dosage matters.
Boultwood J
Blood; 2013 Feb; 121(6):869-71. PubMed ID: 23393017
[No Abstract] [Full Text] [Related]
7. CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers.
Ramdzan ZM; Nepveu A
Nat Rev Cancer; 2014 Oct; 14(10):673-82. PubMed ID: 25190083
[TBL] [Abstract][Full Text] [Related]
8. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Wong JC; Weinfurtner KM; Westover T; Kim J; Lebish EJ; Del Pilar Alzamora M; Huang BJ; Walsh M; Abdelhamed S; Ma J; Klco JM; Shannon K
Leukemia; 2024 May; 38(5):1182-1186. PubMed ID: 38443608
[TBL] [Abstract][Full Text] [Related]
9. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias.
Fischer K; Fröhling S; Scherer SW; McAllister Brown J; Scholl C; Stilgenbauer S; Tsui LC; Lichter P; Döhner H
Blood; 1997 Mar; 89(6):2036-41. PubMed ID: 9058725
[TBL] [Abstract][Full Text] [Related]
10. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.
Wong JC; Zhang Y; Lieuw KH; Tran MT; Forgo E; Weinfurtner K; Alzamora P; Kogan SC; Akagi K; Wolff L; Le Beau MM; Killeen N; Shannon K
Blood; 2010 Jun; 115(22):4524-32. PubMed ID: 20233966
[TBL] [Abstract][Full Text] [Related]
11. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
Hosono N
Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
[TBL] [Abstract][Full Text] [Related]
12. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
Chen C; Liu Y; Rappaport AR; Kitzing T; Schultz N; Zhao Z; Shroff AS; Dickins RA; Vakoc CR; Bradner JE; Stock W; LeBeau MM; Shannon KM; Kogan S; Zuber J; Lowe SW
Cancer Cell; 2014 May; 25(5):652-65. PubMed ID: 24794707
[TBL] [Abstract][Full Text] [Related]
13. Distinct clinical and biological implications of
Aly M; Ramdzan ZM; Nagata Y; Balasubramanian SK; Hosono N; Makishima H; Visconte V; Kuzmanovic T; Adema V; Nazha A; Przychodzen BP; Kerr CM; Sekeres MA; Abazeed ME; Nepveu A; Maciejewski JP
Blood Adv; 2019 Jul; 3(14):2164-2178. PubMed ID: 31320321
[TBL] [Abstract][Full Text] [Related]
14. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN.
Thoennissen NH; Lasho T; Thoennissen GB; Ogawa S; Tefferi A; Koeffler HP
Am J Hematol; 2011 Aug; 86(8):703-5. PubMed ID: 21674579
[No Abstract] [Full Text] [Related]
15. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
Le Beau MM; Espinosa R; Davis EM; Eisenbart JD; Larson RA; Green ED
Blood; 1996 Sep; 88(6):1930-5. PubMed ID: 8822909
[TBL] [Abstract][Full Text] [Related]
17. The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters.
Arthur RK; An N; Khan S; McNerney ME
Nucleic Acids Res; 2017 Jun; 45(11):6350-6361. PubMed ID: 28369554
[TBL] [Abstract][Full Text] [Related]
18. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
Imgruet MK; Lutze J; An N; Hu B; Khan S; Kurkewich J; Martinez TC; Wolfgeher D; Gurbuxani SK; Kron SJ; McNerney ME
Blood; 2021 Sep; 138(9):790-805. PubMed ID: 34473231
[TBL] [Abstract][Full Text] [Related]
19. Inactivating CUX1 mutations promote tumorigenesis.
Wong CC; Martincorena I; Rust AG; Rashid M; Alifrangis C; Alexandrov LB; Tiffen JC; Kober C; ; Green AR; Massie CE; Nangalia J; Lempidaki S; Döhner H; Döhner K; Bray SJ; McDermott U; Papaemmanuil E; Campbell PJ; Adams DJ
Nat Genet; 2014 Jan; 46(1):33-8. PubMed ID: 24316979
[TBL] [Abstract][Full Text] [Related]
20. Genomic studies controvert the existence of the CUX1 p75 isoform.
Krishnan M; Senagolage MD; Baeten JT; Wolfgeher DJ; Khan S; Kron SJ; McNerney ME
Sci Rep; 2022 Jan; 12(1):151. PubMed ID: 34997000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
